Prudent outlook hoping to be uplifted by M&A
19/10/21 -"Despite a stronger-than-guided revenue, Bastide’s improvement in the underlying operating profit is limited by the weaker pricing in the UK respiratory business. Its outlook for next year seems ..."
Pages
51
Language
English
Published on
19/10/21
You may also be interested by these reports :
22/03/24
We have included the announced 1,000-to-1 reverse stock split into our number of shares, following the effectiveness of the share consolidation and ...
22/03/24
We have maintained our assumption and the company’s plan of a €300m capital increase to be completed in 2024, but with an expected subscription price ...
21/03/24
Bastide’s half-year turnover and EBITDA both saw decent yoy growth despite heavier payroll costs, while the underlying operating margin moderately ...
18/03/24
DiaSorin’s 2023 results were in line with street expectations, however the profitability guidance miss disappointed investors. Healthy performance by ...